Deferred Tax Assets, Valuation Allowance of NEXIEN BIOPHARMA, INC. from 30 Jun 2017 to 30 Jun 2024

Taxonomy & unit
us-gaap: USD
Description
Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.
Summary
NEXIEN BIOPHARMA, INC. quarterly Deferred Tax Assets, Valuation Allowance in USD history and change rate from 30 Jun 2017 to 30 Jun 2024.
  • NEXIEN BIOPHARMA, INC. Deferred Tax Assets, Valuation Allowance for the quarter ending 30 Jun 2024 was $726,195, a 5.4% increase year-over-year.
Source SEC data
View on sec.gov
Deferred Tax Assets, Valuation Allowance, Quarterly (USD)
Deferred Tax Assets, Valuation Allowance, YoY Quarterly Change (%)

NEXIEN BIOPHARMA, INC. Quarterly Deferred Tax Assets, Valuation Allowance (USD)

Period Value YoY Chg Change % Date Report Filed Fiscal Year Fiscal Period
Q2 2024 $726,195 +$37,272 +5.4% 30 Jun 2024 10-K 22 Oct 2024 2024 FY
Q2 2023 $688,923 +$38,232 +5.9% 30 Jun 2023 10-K 22 Oct 2024 2024 FY
Q2 2022 $650,691 +$33,370 +5.4% 30 Jun 2022 10-K 28 Sep 2023 2023 FY
Q2 2021 $617,321 +$52,348 +9.3% 30 Jun 2021 10-K 28 Sep 2022 2022 FY
Q2 2020 $564,973 +$94,745 +20% 30 Jun 2020 10-K 12 Oct 2021 2021 FY
Q2 2019 $470,228 -$98,506 -17% 30 Jun 2019 10-K 28 Sep 2020 2020 FY
Q2 2018 $568,734 +$497,789 +702% 30 Jun 2018 10-K 30 Sep 2019 2019 FY
Q2 2017 $70,945 30 Jun 2017 10-K 28 Sep 2018 2018 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.